Patricia Nasshorn - 15 Dec 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Business Officer
Signature
/s/ Patricia Nasshorn by Kerri-Ann Millar, attorney-in-fact
Issuer symbol
CUE
Transactions as of
15 Dec 2021
Net transactions value
$0
Form type
4
Filing time
04 Jan 2022, 16:00:53 UTC
Next filing
29 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 15 Dec 2021 Common Stock 100,000 $11.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in four equal semi-annual installments beginning on June 15, 2022.